Birinapant

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Birinapant
DrugBank Accession Number
DB11782
Background

Birinapant has been investigated for the treatment of Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML).

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 806.957
Monoisotopic: 806.429087881
Chemical Formula
C42H56F2N8O6
Synonyms
  • Birinapant

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Dipeptides
Alternative Parents
N-acyl-alpha amino acids and derivatives / Alpha amino acid amides / Alanine and derivatives / 3-alkylindoles / N-acylpyrrolidines / Substituted pyrroles / Aryl fluorides / Benzenoids / Tertiary carboxylic acid amides / Heteroaromatic compounds
show 9 more
Substituents
3-alkylindole / Alanine or derivatives / Alcohol / Alpha-amino acid amide / Alpha-amino acid or derivatives / Alpha-dipeptide / Amine / Amino acid or derivatives / Aromatic heteropolycyclic compound / Aryl fluoride
show 29 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
6O4Z07B57R
CAS number
1260251-31-7
InChI Key
PKWRMUKBEYJEIX-DXXQBUJASA-N
InChI
InChI=1S/C42H56F2N8O6/c1-7-33(49-39(55)21(3)45-5)41(57)51-19-27(53)15-25(51)17-31-29-11-9-23(43)13-35(29)47-37(31)38-32(30-12-10-24(44)14-36(30)48-38)18-26-16-28(54)20-52(26)42(58)34(8-2)50-40(56)22(4)46-6/h9-14,21-22,25-28,33-34,45-48,53-54H,7-8,15-20H2,1-6H3,(H,49,55)(H,50,56)/t21-,22-,25-,26-,27-,28-,33-,34-/m0/s1
IUPAC Name
(2S)-N-[(2S)-1-[(2R,4S)-2-[(6,6'-difluoro-3'-{[(2R,4S)-4-hydroxy-1-[(2S)-2-[(2S)-2-(methylamino)propanamido]butanoyl]pyrrolidin-2-yl]methyl}-1H,1'H-[2,2'-biindole]-3-yl)methyl]-4-hydroxypyrrolidin-1-yl]-1-oxobutan-2-yl]-2-(methylamino)propanamide
SMILES
CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1CC1=C(NC2=CC(F)=CC=C12)C1=C(C[C@@H]2C[C@H](O)CN2C(=O)[C@H](CC)NC(=O)[C@H](C)NC)C2=CC=C(F)C=C2N1

References

General References
Not Available
PubChem Compound
49836020
PubChem Substance
347828132
ChemSpider
27444380
BindingDB
50071920
ChEMBL
CHEMBL3039522
ZINC
ZINC000096941868
PDBe Ligand
GT6
PDB Entries
4kmp

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2TerminatedTreatmentAbdominal wall neoplasm / Fallopian Tube Neoplasms / Ovarian Cancer (Epithelial)1
2TerminatedTreatmentChronic Myelomonocytic Leukemia (CMML) / Myelodysplastic Syndromes (MDS)1
1CompletedTreatmentMalignancies1
1CompletedTreatmentRelapsed Epithelial Ovarian Cancer / Relapsed Fallopian Tube Cancer / Relapsed Primary Peritoneal Cancer1
1RecruitingTreatmentChondrosarcomas / Chronic Lymphocytic Leukemia (CLL) / Colorectal Carcinoma (CRC) / Malignant Neoplasm of Stomach / Non-Hodgkin's Lymphoma (NHL) / Non-Small Cell Lung Carcinoma (NSCLC) / Sarcomas / Small Lymphocytic Lymphoma / Tumors, Solid1
1RecruitingTreatmentFacial Cancer / Head Cancer / Neck Cancer / Oral Cancers / Upper Aerodigestive Tract Cancer1
1RecruitingTreatmentLocally Recurrent Head and Neck Squamous Cell Carcinoma / Nasopharyngeal Squamous Cell Carcinoma / Sinonasal Squamous Cell Carcinoma1
1TerminatedTreatmentViral Hepatitis B1
1, 2CompletedTreatmentMalignancies1
1, 2CompletedTreatmentMyelodysplastic Syndromes (MDS)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0352 mg/mLALOGPS
logP2.21ALOGPS
logP1.62ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)12.28ChemAxon
pKa (Strongest Basic)8.9ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count8ChemAxon
Polar Surface Area194.92 Å2ChemAxon
Rotatable Bond Count15ChemAxon
Refractivity214.65 m3·mol-1ChemAxon
Polarizability86.23 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 20:47 / Updated on February 21, 2021 18:53